Cargando…

Rituximab treatment in rheumatoid arthritis: how does it work?

Treatment with the chimerical monoclonal antibody rituximab results in CD20-directed B cell depletion. Although this depletion is almost complete in the peripheral blood of nearly all patients with rheumatoid arthritis, a proportion of patients does not exhibit a clinical response. The paper by Nako...

Descripción completa

Detalles Bibliográficos
Autores principales: Boumans, Maria JH, Tak, Paul P
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003538/
https://www.ncbi.nlm.nih.gov/pubmed/20017888
http://dx.doi.org/10.1186/ar2852
_version_ 1782193873253040128
author Boumans, Maria JH
Tak, Paul P
author_facet Boumans, Maria JH
Tak, Paul P
author_sort Boumans, Maria JH
collection PubMed
description Treatment with the chimerical monoclonal antibody rituximab results in CD20-directed B cell depletion. Although this depletion is almost complete in the peripheral blood of nearly all patients with rheumatoid arthritis, a proportion of patients does not exhibit a clinical response. The paper by Nakou and colleagues suggests that a decrease in CD19+CD27+ memory B cells in both peripheral blood and bone marrow precedes the clinical response to rituximab. This finding adds to the emerging evidence that lack of response to rituximab is associated with persistence of B lineage cells in specific body compartments.
format Text
id pubmed-3003538
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30035382010-12-18 Rituximab treatment in rheumatoid arthritis: how does it work? Boumans, Maria JH Tak, Paul P Arthritis Res Ther Editorial Treatment with the chimerical monoclonal antibody rituximab results in CD20-directed B cell depletion. Although this depletion is almost complete in the peripheral blood of nearly all patients with rheumatoid arthritis, a proportion of patients does not exhibit a clinical response. The paper by Nakou and colleagues suggests that a decrease in CD19+CD27+ memory B cells in both peripheral blood and bone marrow precedes the clinical response to rituximab. This finding adds to the emerging evidence that lack of response to rituximab is associated with persistence of B lineage cells in specific body compartments. BioMed Central 2009 2009-11-24 /pmc/articles/PMC3003538/ /pubmed/20017888 http://dx.doi.org/10.1186/ar2852 Text en Copyright ©2009 BioMed Central Ltd
spellingShingle Editorial
Boumans, Maria JH
Tak, Paul P
Rituximab treatment in rheumatoid arthritis: how does it work?
title Rituximab treatment in rheumatoid arthritis: how does it work?
title_full Rituximab treatment in rheumatoid arthritis: how does it work?
title_fullStr Rituximab treatment in rheumatoid arthritis: how does it work?
title_full_unstemmed Rituximab treatment in rheumatoid arthritis: how does it work?
title_short Rituximab treatment in rheumatoid arthritis: how does it work?
title_sort rituximab treatment in rheumatoid arthritis: how does it work?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003538/
https://www.ncbi.nlm.nih.gov/pubmed/20017888
http://dx.doi.org/10.1186/ar2852
work_keys_str_mv AT boumansmariajh rituximabtreatmentinrheumatoidarthritishowdoesitwork
AT takpaulp rituximabtreatmentinrheumatoidarthritishowdoesitwork